Treatment Options in Hormone-Refractory Prostate Cancer
- 1 January 2001
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 61 (15) , 2177-2192
- https://doi.org/10.2165/00003495-200161150-00003
Abstract
Prostate cancer is the second leading cause of cancer mortality among men in Western countries. The initial treatment of advanced prostate cancer is suppression of testicular androgen production by...Keywords
This publication has 124 references indexed in Scilit:
- A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinomaCancer, 2000
- PC-SPES: A unique inhibitor of proliferation of prostate cancer cells in vitro and in vivoThe Prostate, 2000
- Effects of a phytotherapeutic agent, PC‐SPES, on prostate cancer: a preliminary investigation on human cell lines and patientsBJU International, 1999
- Efficacy and Concentration-Response of Murine Anti-VEGF Monoclonal Antibody in Tumor-Bearing Mice and Extrapolation to HumansToxicologic Pathology, 1999
- How Much Can We Rely on the Level of Prostate-Specific Antigen as an End Point for Evaluation of Clinical Trials? A Word of Caution!JNCI Journal of the National Cancer Institute, 1996
- Estramustine Phosphate SodiumDrugs & Aging, 1995
- Mutation of the Androgen-Receptor Gene in Metastatic Androgen-Independent Prostate CancerNew England Journal of Medicine, 1995
- Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivoNature, 1993
- A phase II randomized trial of megestrol acetate or dexamethasone in the treatment of hormonally refractory advanced carcinoma of the prostateCancer, 1990
- Leuprolide versus Diethylstilbestrol for Metastatic Prostate CancerNew England Journal of Medicine, 1984